Passage Bio, Inc. (PASG)

On our desk, PASG's 16% after-hours plunge following the Remix Therapeutics merger announcement highlights deep retail frustration over a lack of transaction details. With legacy Passage Bio shareholders receiving only a small fractional stake in the combined entity, the market is aggressively pricing in severe dilution. We are treating this strictly as a distressed asset trade where ongoing viability hinges entirely on the merger closing.

From a clinical research perspective, the strategic pivot away from our central nervous system AAV gene therapies to whatever platform Remix Therapeutics brings alters the entire scientific thesis. We are no longer evaluating a specialized neurodegenerative pipeline; instead, we are watching a corporate shell absorb a private entity under severe capital constraints. Clinical trial catalysts for legacy programs are effectively dead.

Our quant models spit out a weak Quality Score of 3.9/10, yet the CirclFi valuation engine flags minimal immediate value-trap risk due to its depressed $4.59 share price and micro-cap status around $15M market cap. However, analysts from TD Cowen and Chardan have previously downgraded or sidelined the stock to hold/neutral ratings, reflecting widespread institutional caution before the merger details surfaced.

Looking at the Q2 2026 numbers, the reported net loss of $7.82M represents a slight bottom-line beat against consensus, but looking past the headline reveals zero revenue and a cash reserve dwindling to $24.2M. With less than a year of runway remaining and a 75% workforce reduction already executed alongside the winding down of AAV gene therapy programs, the fundamental risk profile remains deeply distressed.

Watching the daily tape, volume has completely dried up—dropping 43% below average session volume during late-July trading before the massive merger volatility hit. With 52-week ranges swinging wildly between $3 and $20, and institutional coverage sparse, liquidity risk is a primary concern for any position sizing in this ticker right now.